Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Apellis Pharmaceuticals (APLS) Gross Profit (2021 - 2025)

Apellis Pharmaceuticals has reported Gross Profit over the past 5 years, most recently at $170.2 million for Q4 2025.

  • Quarterly results put Gross Profit at $170.2 million for Q4 2025, down 0.86% from a year ago — trailing twelve months through Dec 2025 was $901.5 million (up 35.85% YoY), and the annual figure for FY2025 was $901.5 million, up 35.85%.
  • Gross Profit for Q4 2025 was $170.2 million at Apellis Pharmaceuticals, down from $434.0 million in the prior quarter.
  • Over the last five years, Gross Profit for APLS hit a ceiling of $434.0 million in Q3 2025 and a floor of $5.5 million in Q3 2021.
  • Median Gross Profit over the past 5 years was $107.2 million (2023), compared with a mean of $113.3 million.
  • Biggest five-year swings in Gross Profit: plummeted 67.23% in 2022 and later surged 540.72% in 2023.
  • Apellis Pharmaceuticals' Gross Profit stood at $60.2 million in 2021, then plummeted by 67.23% to $19.7 million in 2022, then surged by 540.72% to $126.5 million in 2023, then skyrocketed by 35.75% to $171.7 million in 2024, then fell by 0.86% to $170.2 million in 2025.
  • The last three reported values for Gross Profit were $170.2 million (Q4 2025), $434.0 million (Q3 2025), and $164.9 million (Q2 2025) per Business Quant data.